January 17, 2025
LAS VEGAS — New research findings from Visioneering Technologies Inc. (VTI) are highlighting another benefit of NaturalVue Multifocal contact lenses — correcting astigmatism. The data is from a clinical trial led by Professor Gonzalo Carracedo (Universidad Complutense de Madrid) on astigmatism correction in myopic children and updates from VTI’s ongoing PROTECT study.
Presented in a poster session and a presentation titled, “Evaluation of Visual Acuity with Multifocal Catenary Curve-Based Contact Lens Design in Different Degrees of Astigmatism” at the Global Specialty Lens Symposium (GSLS), the following are the key findings from the study:
- Astigmatic Vision Correction:
- 100% success with astigmatism ≤ 2.00D
- 83% success with astigmatism ≤ 3.00D
- Patient Experience:
- 77% rated overall visual quality as satisfactory or better.
- 83% rated overall comfort as satisfactory or better.
- Additional Benefits: Preserved stereopsis and compatibility across pupil sizes.
This clinical trial validated the NaturalVue Multifocal lens astigmatism correction indication of up to 2.00D. NaturalVue Multifocal, can correct (vs. mask) an extensive range of astigmatism by enabling both meridians to focus simultaneously due to its patented extended depth of focus design.
“Professor Carracedo’s study highlights NaturalVue’s ability to provide exceptional vision while managing myopia, empowering kids to thrive without compromise,” Dr. Ashley Tuan, VTI’s Chief Medical Officer said.
